<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40071757</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associated With Response in Locally Advanced Rectal Cancer.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>725</EndPage><MedlinePgn>713-725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003660</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The extent of neoadjuvant therapy response, before surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored. Within operable colorectal cancer, circulating markers of elevated systemic inflammation are associated with poor survival. Studies have suggested that elevated pre-neoadjuvant inflammatory markers, including the modified Glasgow prognostic score and the neutrophil:lymphocyte ratio, are associated with a poorer response.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to comprehensively evaluate hematological markers of inflammation before and after neoadjuvant therapy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Single health board from a prospectively maintained regional cancer database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive patients with locally advanced rectal cancer who underwent curative-intent neoadjuvant therapy between June 2016 and July 2021.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Elevated markers of the systemic inflammatory response before and after neoadjuvant therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 278 patients (67.3% men, median age 65 years) were identified. A complete response (clinical or pathological complete response) was achieved in 27.34%, and good tumor regression was achieved in 37.05% (tumor regression grading 0-1). No pre-neoadjuvant marker was found to be associated with response or regression. Multivariate analysis of post-neoadjuvant variables revealed an elevated modified Glasgow prognostic score (OR 2.8; 95% CI, 1.22-6.41; p = 0.015), and an elevated CEA (OR 4.09; 95% CI, 1.6-10.44; p = 0.003) was found to be independently associated with incomplete response. An elevated post-neoadjuvant modified Glasgow prognostic score (OR 2.14; 95% CI, 1.08-4.23; p = 0.029) was also independently associated with poor tumor regression on multivariate analysis.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design and slight variation in the timing of post-neoadjuvant blood tests were limitations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report that post-neoadjuvant modified Glasgow prognostic score is associated with poorer response and regression, potentially indicating that radiation resistance is associated with the development of a protumor inflammatory environment. Further work is required to define the local intratumoral processes associated with response and their interrelationship with systemic parameters. Ultimately, there may be a rationale for testing anti-inflammatory strategies in combination with radiotherapy as an option for optimizing treatment response. See Video Abstract .</AbstractText><AbstractText Label="LOS MARCADORES CIRCULANTES DE INFLAMACIN SISTMICA, MEDIDOS DESPUS DE COMPLETAR LA TERAPIA NEOADYUVANTE, SE ASOCIAN CON LA RESPUESTA EN EL CNCER RECTAL LOCALMENTE AVANZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:El grado de respuesta a la terapia neoadyuvante, antes de la cirug&#xed;a, es un pronosticador importante en el c&#xe1;ncer rectal localmente avanzado. Existe un espectro de respuestas, con una escasez de medidas confiables. La respuesta del hu&#xe9;sped al tratamiento permanece inexplorada. Dentro del c&#xe1;ncer colorrectal operable, los marcadores circulantes de inflamaci&#xf3;n sist&#xe9;mica elevada se asocian con una supervivencia deficiente. Los estudios han sugerido que los marcadores inflamatorios pre-neoadyuvantes elevados, incluidos; el puntaje pron&#xf3;stico de Glasgow modificado y la proporci&#xf3;n neutr&#xf3;filos::linfocitos, se asocian con una respuesta peor.OBJETIVO:Este estudio tuvo como objetivo evaluar de manera integral los marcadores hematol&#xf3;gicos de inflamaci&#xf3;n antes y despu&#xe9;s de la terapia neoadyuvante.DISE&#xd1;O:Estudio de cohorte longitudinal.ESCENARIO:Junta de salud &#xfa;nica de una base de datos de c&#xe1;ncer regional mantenida prospectivamente.PACIENTES:Pacientes consecutivos con c&#xe1;ncer rectal localmente avanzado que se sometieron a terapia neoadyuvante con intenci&#xf3;n curativa entre; Junio de 2016-julio de 2021.PRINCIPALES MEDIDAS DE RESULTADOS:Marcadores elevados de la respuesta inflamatoria sist&#xe9;mica antes y despu&#xe9;s de la terapia neoadyuvante.RESULTADOS:278 pacientes. 67,3 % varones, mediana de edad 65. El 27,34 % logr&#xf3; una "respuesta completa" (respuesta completa cl&#xed;nica o patol&#xf3;gica). El 37,05 % logr&#xf3; una "buena regresi&#xf3;n tumoral" (clasificaci&#xf3;n de regresi&#xf3;n tumoral de 0 a 1). Ning&#xfa;n marcador pre-neoadyuvante se asoci&#xf3; con la respuesta o la regresi&#xf3;n. El an&#xe1;lisis multivariado de las variables pos-neoadyuvantes revel&#xf3; un puntaje pron&#xf3;stico de Glasgow modificado elevado (OR 2,8; IC del 95 % 1,22-6,41; p = 0,015) y un ant&#xed;geno carcinoembrionario elevado (OR 4,09; IC del 95 % 1,6-10,44; p = 0,003) asociados de forma independiente con una respuesta incompleta. Un puntaje pron&#xf3;stico de Glasgow modificado post-neoadyuvante elevado (OR 2,14, IC del 95 % 1,08-4,23, p = 0,029) tambi&#xe9;n se asoci&#xf3; de forma independiente con una regresi&#xf3;n tumoral deficiente en el an&#xe1;lisis multivariable.LIMITACIONES:Dise&#xf1;o retrospectivo. Ligera variaci&#xf3;n en el momento de los an&#xe1;lisis de sangre pos-neoadyuvante.CONCLUSIONES:Informamos que el puntaje pron&#xf3;stico de Glasgow modificado pos-neoadyuvante se asoci&#xf3; con una respuesta y regresi&#xf3;n m&#xe1;s deficientes, lo que podr&#xed;a indicar que la resistencia a la radiaci&#xf3;n est&#xe1; asociada con el desarrollo de un entorno inflamatorio protumoral. Se requieren m&#xe1;s estudios para definir los procesos intratumorales locales asociados con la respuesta y su interrelaci&#xf3;n con los par&#xe1;metros sist&#xe9;micos. En &#xfa;ltima instancia, puede haber una justificaci&#xf3;n para probar estrategias antiinflamatorias en combinaci&#xf3;n con radioterapia como una opci&#xf3;n para optimizar la respuesta al tratamiento. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Ross K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Cathail</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Garscube Estate, Bearsden, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Harikrishnan S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Jonathan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Radiology/Imaging Department, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Donald C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horgan</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roxburgh</LastName><ForeName>Campbell S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical complete response</Keyword><Keyword MajorTopicYN="N">Locally advanced rectal cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant</Keyword><Keyword MajorTopicYN="N">Organ preservation</Keyword><Keyword MajorTopicYN="N">Pathological complete response</Keyword><Keyword MajorTopicYN="N">Rectal cancer</Keyword><Keyword MajorTopicYN="N">Systemic inflammatory response</Keyword><Keyword MajorTopicYN="N">Tumor regression</Keyword><Keyword MajorTopicYN="N">modified Glasgow prognostic score</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>12</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40071757</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003660</ArticleId><ArticleId IdType="pii">00003453-202506000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22&#x2013;iv40.</Citation></Reference><Reference><Citation>Fokas E, Str&#xf6;bel P, Fietkau R, et al.; German Rectal Cancer Study Group. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst. 2017;109. doi:10.1093/jnci/djx095.</Citation></Reference><Reference><Citation>Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918&#x2013;928.</Citation></Reference><Reference><Citation>Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2030097.</Citation></Reference><Reference><Citation>Sell NM, Qwaider YZ, Goldstone RN, et al. Ten-year survival after pathologic complete response in rectal adenocarcinoma. J Surg Oncol. 2021;123:293&#x2013;298.</Citation></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation></Reference><Reference><Citation>Kong JC, Guerra GR, Warrier SK, et al. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2018;20:574&#x2013;585.</Citation></Reference><Reference><Citation>Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926&#x2013;1933.</Citation></Reference><Reference><Citation>Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.</Citation></Reference><Reference><Citation>Loughrey MB, Webster F, Arends MJ, et al. Dataset for pathology reporting of colorectal cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Ann Surg. 2022;275:e549&#x2013;e561.</Citation></Reference><Reference><Citation>Dreyer SB, Powell AG, McSorley ST, et al. The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Ann Surg Oncol. 2017;24:1295&#x2013;1303.</Citation></Reference><Reference><Citation>Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori. 2019;105:434&#x2013;440.</Citation></Reference><Reference><Citation>Bong JW, Lim SB, Ryu H, et al. Effect of anaemia on the response to preoperative chemoradiotherapy for rectal cancer. ANZ J Surg. 2021;91:E286&#x2013;E291.</Citation></Reference><Reference><Citation>Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol. 2020;26:7022&#x2013;7035.</Citation></Reference><Reference><Citation>Machado Carvalho JV, Dutoit V, Corr&#xf2; C, Koessler T. Promises and challenges of predictive blood biomarkers for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cells. 2023;12:413.</Citation></Reference><Reference><Citation>Lai S, Huang L, Luo S, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett. 2020;20:2763&#x2013;2770.</Citation></Reference><Reference><Citation>Wu Z, Zhang J, Cai Y, et al. Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. Medicine (Baltim). 2018;97:e11435.</Citation></Reference><Reference><Citation>Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249:788&#x2013;793.</Citation></Reference><Reference><Citation>McMahon R, O&#x2019;Cathail SM, Steele C, Platt J, Horgan P, Roxburgh CS. Circulating markers of systemic inflammation, measured after completion of neoadjuvant therapy, independently predict response in locally advanced rectal cancer [ASCRS abstract T101]. Dis Colon Rectum. 2024;67:e499&#x2013;e500.</Citation></Reference><Reference><Citation>He L, Li H, Cai J, et al. Prognostic value of the Glasgow prognostic score or modified Glasgow prognostic score for patients with colorectal cancer receiving various treatments: a systematic review and meta-analysis. Cell Physiol Biochem. 2018;51:1237&#x2013;1249.</Citation></Reference><Reference><Citation>Xu N, Li W, Huang F, et al. Systemic inflammation-based predictors of pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. J Cancer Res Ther. 2022;18:438&#x2013;444.</Citation></Reference><Reference><Citation>Jeon BH, Shin US, Moon SM, et al. Neutrophil to lymphocyte ratio: a predictive marker for treatment outcomes in patients with rectal cancer who underwent neoadjuvant chemoradiation followed by surgery. Ann Coloproctol. 2019;35:100&#x2013;106.</Citation></Reference><Reference><Citation>Li A, He K, Guo D, et al. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer. Future Oncol. 2019;15:3233&#x2013;3242.</Citation></Reference><Reference><Citation>Lee H, Park HC, Park W, et al. Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer. Radiat Oncol J. 2012;30:117&#x2013;123.</Citation></Reference><Reference><Citation>Gray S, Axelsson B. The prevalence of deranged C-reactive protein and albumin in patients with incurable cancer approaching death. PLoS One. 2018;13:e0193693.</Citation></Reference><Reference><Citation>Arends J, Strasser F, Gonella S, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open. 2021;6:100092.</Citation></Reference><Reference><Citation>Swanton C, Bernard E, Abbosh C, et al. Embracing cancer complexity: Hallmarks of systemic disease. Cell. 2024;187:1589&#x2013;1616.</Citation></Reference><Reference><Citation>Saal J, Bald T, Eckstein M, et al. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition. Lung Cancer. 2024;189:107505.</Citation></Reference><Reference><Citation>Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.</Citation></Reference><Reference><Citation>Partl R, Lukasiak K, Thurner EM, Renner W, Stranzl-Lawatsch H, Langsenlehner T. The elevated pre-treatment C-reactive protein predicts poor prognosis in patients with locally advanced rectal cancer treated with neo-adjuvant radiochemotherapy. Diagnostics (Basel). 2020;10:780.</Citation></Reference><Reference><Citation>Li M, Xiao Q, Venkatachalam N, et al. Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. Ther Adv Med Oncol. 2022;14:17588359221077972.</Citation></Reference><Reference><Citation>Chandramohan A, Mittal R, Dsouza R, et al. Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis. 2022;24:428&#x2013;438.</Citation></Reference><Reference><Citation>Hanna CR, O&#x2019;Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol. 2021;16:163.</Citation></Reference><Reference><Citation>Groarke JD, Crawford J, Collins SM, et al. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024;391:2291&#x2013;2303.</Citation></Reference><Reference><Citation>Shi X, Zhao M, Shi B, et al. Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front Oncol. 2022;12:916840.</Citation></Reference><Reference><Citation>Eastern Rectal Cancer Response Collaborative, Ireland. A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2022;37:957&#x2013;965.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37682775</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>A Longitudinal MRI-Based Artificial Intelligence System to Predict Pathological Complete Response After Neoadjuvant Therapy in Rectal Cancer: A Multicenter Validation Study.</ArticleTitle><Pagination><StartPage>e1195</StartPage><EndPage>e1206</EndPage><MedlinePgn>e1195-e1206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002931</ELocationID><Abstract><AbstractText Label="BACKGROUND">Accurate prediction of response to neoadjuvant chemoradiotherapy is critical for subsequent treatment decisions for patients with locally advanced rectal cancer.</AbstractText><AbstractText Label="OBJECTIVE">To develop and validate a deep learning model based on the comparison of paired MRI before and after neoadjuvant chemoradiotherapy to predict pathological complete response.</AbstractText><AbstractText Label="DESIGN">By capturing the changes from MRI before and after neoadjuvant chemoradiotherapy in 638 patients, we trained a multitask deep learning model for response prediction (DeepRP-RC) that also allowed simultaneous segmentation. Its performance was independently tested in an internal and 3 external validation sets, and its prognostic value was also evaluated.</AbstractText><AbstractText Label="SETTINGS">Multicenter study.</AbstractText><AbstractText Label="PATIENTS">We retrospectively enrolled 1201 patients diagnosed with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy before total mesorectal excision. Patients had been treated at 1 of 4 hospitals in China between January 2013 and December 2020.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The main outcome was the accuracy of predicting pathological complete response, measured as the area under receiver operating curve for the training and validation data sets.</AbstractText><AbstractText Label="RESULTS">DeepRP-RC achieved high performance in predicting pathological complete response after neoadjuvant chemoradiotherapy, with area under the curve values of 0.969 (0.942-0.996), 0.946 (0.915-0.977), 0.943 (0.888-0.998), and 0.919 (0.840-0.997) for the internal and 3 external validation sets, respectively. DeepRP-RC performed similarly well in the subgroups defined by receipt of radiotherapy, tumor location, T/N stages before and after neoadjuvant chemoradiotherapy, and age. Compared with experienced radiologists, the model showed substantially higher performance in pathological complete response prediction. The model was also highly accurate in identifying the patients with poor response. Furthermore, the model was significantly associated with disease-free survival independent of clinicopathological variables.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its retrospective design and absence of multiethnic data.</AbstractText><AbstractText Label="CONCLUSIONS">DeepRP-RC could be an accurate preoperative tool for pathological complete response prediction in rectal cancer after neoadjuvant chemoradiotherapy.</AbstractText><AbstractText Label="UN SISTEMA DE IA BASADO EN RESONANCIA MAGNTICA LONGITUDINAL PARA PREDECIR LA RESPUESTA PATOLGICA COMPLETA DESPUS DE LA TERAPIA NEOADYUVANTE EN EL CNCER DE RECTO UN ESTUDIO DE VALIDACIN MULTICNTRICO">ANTECEDENTES:La predicci&#xf3;n precisa de la respuesta a la quimiorradioterapia neoadyuvante es fundamental para las decisiones de tratamiento posteriores para los pacientes con c&#xe1;ncer de recto localmente avanzado.OBJETIVO:Desarrollar y validar un modelo de aprendizaje profundo basado en la comparaci&#xf3;n de resonancias magn&#xe9;ticas pareadas antes y despu&#xe9;s de la quimiorradioterapia neoadyuvante para predecir la respuesta patol&#xf3;gica completa.DISE&#xd1;O:Al capturar los cambios de las im&#xe1;genes de resonancia magn&#xe9;tica antes y despu&#xe9;s de la quimiorradioterapia neoadyuvante en 638 pacientes, entrenamos un modelo de aprendizaje profundo multitarea para la predicci&#xf3;n de respuesta (DeepRP-RC) que tambi&#xe9;n permiti&#xf3; la segmentaci&#xf3;n simult&#xe1;nea. Su rendimiento se prob&#xf3; de forma independiente en un conjunto de validaci&#xf3;n interna y tres externas, y tambi&#xe9;n se evalu&#xf3; su valor pron&#xf3;stico.ESCENARIO:Estudio multic&#xe9;ntrico.PACIENTES:Volvimos a incluir retrospectivamente a 1201 pacientes diagnosticados con c&#xe1;ncer de recto localmente avanzado y sometidos a quimiorradioterapia neoadyuvante antes de la escisi&#xf3;n total del mesorrecto. Eran de cuatro hospitales en China en el per&#xed;odo entre enero de 2013 y diciembre de 2020.PRINCIPALES MEDIDAS DE RESULTADO:Los principales resultados fueron la precisi&#xf3;n de la predicci&#xf3;n de la respuesta patol&#xf3;gica completa, medida como el &#xe1;rea bajo la curva operativa del receptor para los conjuntos de datos de entrenamiento y validaci&#xf3;n.RESULTADOS:DeepRP-RC logr&#xf3; un alto rendimiento en la predicci&#xf3;n de la respuesta patol&#xf3;gica completa despu&#xe9;s de la quimiorradioterapia neoadyuvante, con valores de &#xe1;rea bajo la curva de 0,969 (0,942-0,996), 0,946 (0,915-0,977), 0,943 (0,888-0,998), y 0,919 (0,840-0,997) para los conjuntos de validaci&#xf3;n interna y las tres externas, respectivamente. DeepRP-RC se desempe&#xf1;&#xf3; de manera similar en los subgrupos definidos por la recepci&#xf3;n de radioterapia, la ubicaci&#xf3;n del tumor, los estadios T/N antes y despu&#xe9;s de la quimiorradioterapia neoadyuvante y la edad. En comparaci&#xf3;n con los radi&#xf3;logos experimentados, el modelo mostr&#xf3; un rendimiento sustancialmente mayor en la predicci&#xf3;n de la respuesta patol&#xf3;gica completa. El modelo tambi&#xe9;n fue muy preciso en la identificaci&#xf3;n de los pacientes con mala respuesta. Adem&#xe1;s, el modelo se asoci&#xf3; significativamente con la supervivencia libre de enfermedad independientemente de las variables clinicopatol&#xf3;gicas.LIMITACIONES:Este estudio estuvo limitado por el dise&#xf1;o retrospectivo y la ausencia de datos multi&#xe9;tnicos.CONCLUSIONES:DeepRP-RC podr&#xed;a servir como una herramienta preoperatoria precisa para la predicci&#xf3;n de la respuesta patol&#xf3;gica completa en el c&#xe1;ncer de recto despu&#xe9;s de la quimiorradioterapia neoadyuvante. (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jinghua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Haimei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Songbing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Peirong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hengyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Wuteng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruijiang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, School of Medicine, Stanford University, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaojian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37682775</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002931</ArticleId><ArticleId IdType="pii">00003453-202312000-00006</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Ma B, Gao P, Wang H, et al. What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer. 2017;141:1052&#x2013;1065.</Citation></Reference><Reference><Citation>Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440&#x2013;448.</Citation></Reference><Reference><Citation>Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847&#x2013;1858.</Citation></Reference><Reference><Citation>Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16:1537&#x2013;1546.</Citation></Reference><Reference><Citation>Wang T, Wang J, Deng Y, Wu X, Wang L. Neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer. Gastroenterol Rep (Oxf). 2014;2:37&#x2013;43.</Citation></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation></Reference><Reference><Citation>Gani C, Bonomo P, Zwirner K, et al. Organ preservation in rectal cancer&#x2014;challenges and future strategies. Clin Transl Radiat Oncol. 2017;3:9&#x2013;15.</Citation></Reference><Reference><Citation>Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging&#x2014;a meta-analysis. Radiology. 2004;232:773&#x2013;783.</Citation></Reference><Reference><Citation>Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357:497&#x2013;504.</Citation></Reference><Reference><Citation>Beets-Tan RG, Lambregts DM, Maas M, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2013;23:2522&#x2013;2531.</Citation></Reference><Reference><Citation>Beets-Tan RG, Beets GL. MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. Nat Rev Gastroenterol Hepatol. 2014;11:480&#x2013;488.</Citation></Reference><Reference><Citation>van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology. 2013;269:101&#x2013;112.</Citation></Reference><Reference><Citation>Zhao RS, Wang H, Zhou ZY, Zhou Q, Mulholland MW. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. Dis Colon Rectum. 2014;57:388&#x2013;395.</Citation></Reference><Reference><Citation>Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115&#x2013;118.</Citation></Reference><Reference><Citation>Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316:2402&#x2013;2410.</Citation></Reference><Reference><Citation>Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al.; the CAMELYON16 Consortium. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA. 2017;318:2199&#x2013;2210.</Citation></Reference><Reference><Citation>Chilamkurthy S, Ghosh R, Tanamala S, et al. Deep learning algorithms for detection of critical findings in head CT scans: a retrospective study. Lancet. 2018;392:2388&#x2013;2396.</Citation></Reference><Reference><Citation>Li Y, Liu W, Pei Q, et al. Predicting pathological complete response by comparing MRI-based radiomics pre- and postneoadjuvant radiotherapy for locally advanced rectal cancer. Cancer Med. 2019;8:7244&#x2013;7252.</Citation></Reference><Reference><Citation>Nie K, Shi L, Chen Q, et al. Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin Cancer Res. 2016;22:5256&#x2013;5264.</Citation></Reference><Reference><Citation>Jin C, Yu H, Ke J, et al. Predicting treatment response from longitudinal images using multi-task deep learning. Nat Commun. 2021;12:1851.</Citation></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.</Citation></Reference><Reference><Citation>Nagendran M, Chen Y, Lovejoy CA, et al. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. BMJ. 2020;368:m689.</Citation></Reference><Reference><Citation>&#xc7;i&#xe7;ek &#xd6;, Abdulkadir A, Lienkamp SS, Brox T, Ronneberger O. 3D U-Net: learning dense volumetric segmentation from sparse annotation. In: Medical Image Computing and Computer-Assisted Intervention&#x2013;MICCAI 2016: 19th International Conference; Proceedings, Part II 19; October 17&#x2013;21, 2016; Athens, Greece: Springer International Publishing; 424&#x2013;432.</Citation></Reference><Reference><Citation>Bosset JF, Collette L, Calais G, et al.; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114&#x2013;1123.</Citation></Reference><Reference><Citation>Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223&#x2013;3233.</Citation></Reference><Reference><Citation>Zhang J, Huang M, Cai Y, et al. Neoadjuvant chemotherapy with mFOLFOXIRI without routine use of radiotherapy for locally advanced rectal cancer. Clin Colorectal Cancer. 2019;18:238&#x2013;244.</Citation></Reference><Reference><Citation>Trakarnsanga A, G&#xf6;nen M, Shia J, et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J Natl Cancer Inst. 2014;106:dju248.</Citation></Reference><Reference><Citation>Milletari F, Navab N, Ahmadi SA. V-Net: fully convolutional neural networks for volumetric medical image segmentation. In: 2016 Fourth International Conference on 3D Vision (3DV). IEEE Computer Society; 2016:565&#x2013;571; CA, USA.</Citation></Reference><Reference><Citation>Zhuo J, Gullapalli RP. AAPM/RSNA physics tutorial for residents: MR artifacts, safety, and quality control. Radiographics. 2006;26:275&#x2013;297.</Citation></Reference><Reference><Citation>Morelli JN, Runge VM, Ai F, et al. An image-based approach to understanding the physics of MR artifacts. Radiographics. 2011;31:849&#x2013;866.</Citation></Reference><Reference><Citation>Armstrong D, Raissouni S, Price Hiller J, et al. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin Colorectal Cancer. 2015;14:291&#x2013;295.</Citation></Reference><Reference><Citation>Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2016;23:1177&#x2013;1186.</Citation></Reference><Reference><Citation>Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019;29:1211&#x2013;1220.</Citation></Reference><Reference><Citation>Shaish H, Aukerman A, Vanguri R, et al. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study. Eur Radiol. 2020;30:6263&#x2013;6273.</Citation></Reference><Reference><Citation>Jang BS, Lim YJ, Song C, et al. Image-based deep learning model for predicting pathological response in rectal cancer using post-chemoradiotherapy magnetic resonance imaging. Radiother Oncol. 2021;161:183&#x2013;190.</Citation></Reference><Reference><Citation>Mohiuddin M, Marks G, Bannon J. High-dose preoperative radiation and full thickness local excision: a new option for selected T3 distal rectal cancers. Int J Radiat Oncol Biol Phys. 1994;30:845&#x2013;849.</Citation></Reference><Reference><Citation>Kim CJ, Yeatman TJ, Coppola D, et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234:352&#x2013;358.</Citation></Reference><Reference><Citation>Smith FM, Ahad A, Perez RO, Marks J, Bujko K, Heald RJ. Local excision techniques for rectal cancer after neoadjuvant chemoradiotherapy: what are we doing? Dis Colon Rectum. 2017;60:228&#x2013;239.</Citation></Reference><Reference><Citation>Perez RO, Pereira DD, Proscurshim I, et al. Lymph node size in rectal cancer following neoadjuvant chemoradiation&#x2014;can we rely on radiologic nodal staging after chemoradiation? Dis Colon Rectum. 2009;52:1278&#x2013;1284.</Citation></Reference><Reference><Citation>Pomerri F, Pucciarelli S, Maretto I, et al. Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery. 2011;149:56&#x2013;64.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35067503</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in ypT0-1 Rectal Cancer After Preoperative Radiochemotherapy: Postoperative Morbidity, Functional Results, and Long-term Oncologic Outcome.</ArticleTitle><Pagination><StartPage>1306</StartPage><EndPage>1315</EndPage><MedlinePgn>1306-1315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002255</ELocationID><Abstract><AbstractText Label="BACKGROUND">In patients with locally advanced extraperitoneal rectal cancer, a multidisciplinary approach represents the standard treatment. However, considering the favorable prognosis in patients with major or complete response, radical surgery might represent overtreatment.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to evaluate postoperative short-term morbidity, functional outcome, and oncologic long-term outcome in patients with rectal cancer treated with local excision by transanal endoscopic microsurgery or radical surgery and to determine who achieved a complete or major pathological response (ypT0-1) after neoadjuvant treatment.</AbstractText><AbstractText Label="DESIGN">This was a retrospective study.</AbstractText><AbstractText Label="SETTING">The study was conducted at a single center.</AbstractText><AbstractText Label="PATIENTS">Patients who had received neoadjuvant treatment by local excision with a major or complete pathological response at histological examination (transanal endoscopic microsurgery group) were compared to patients treated by radical surgery with the same pathological response (total mesorectal excision group).</AbstractText><AbstractText Label="INTERVENTIONS">The interventions included local excision by transanal endoscopic microsurgery and radical surgery with total mesorectal excision.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Postoperative short-term morbidity, functional outcome 1 year after surgery, and oncologic long-term outcome were measured.</AbstractText><AbstractText Label="RESULTS">Ninety-three patients were included in the study (35 in the transanal endoscopic microsurgery group and 58 in the mesorectal excision group). In the total mesorectal excision group, a sphincter-saving approach was possible in 89.7% (vs 100%; p = 0.049); a protective temporary stoma was necessary in 74.1% of radical procedures (vs 0%; p &lt; 0.001), and 13.8% of these became permanent. Short-term postoperative morbidity was lower after local excision (14.3% vs 46.6%; p = 0.002). One year after surgery, the transanal endoscopic microsurgery group recorded better evacuation and continence function than the total mesorectal excision group. Oncologic outcome was similar between the groups.</AbstractText><AbstractText Label="LIMITATIONS">This study had a retrospective design.</AbstractText><AbstractText Label="CONCLUSION">If a major or complete pathological response occurs after neoadjuvant treatment, an organ-sparing approach by local excision seems to offer the same oncologic results as radical surgery, but it has a better postoperative morbidity rate and better functional results. See Video Abstract at http://links.lww.com/DCR/B901 .Microcirug&#xed;a endosc&#xf3;pica transanal versus escisi&#xf3;n total del mesorrecto en c&#xe1;ncer de recto ypT0-1 despu&#xe9;s de radioquimioterapia preoperatoria: morbilidad posoperatoria, resultados funcionales y resultado oncol&#xf3;gico a largo plazo.</AbstractText><AbstractText Label="ANTECEDENTES">En pacientes con c&#xe1;ncer rectal extraperitoneal localmente avanzado, un abordaje multidisciplinario con radioquimioterapia preoperatoria y cirug&#xed;a con escisi&#xf3;n total del mesorrecto representa el tratamiento est&#xe1;ndar. En pacientes que obtienen una respuesta mayor o completa, la cirug&#xed;a radical puede representar un sobretratamiento, considerando el pron&#xf3;stico favorable de estos casos.</AbstractText><AbstractText Label="OBJETIVO">Evaluar la morbilidad posoperatoria a corto plazo, el resultado funcional y el resultado oncol&#xf3;gico a largo plazo en pacientes con c&#xe1;ncer de recto tratados con escisi&#xf3;n local mediante microcirug&#xed;a endosc&#xf3;pica transanal o mediante cirug&#xed;a radical y que obtuvieron una respuesta patol&#xf3;gica completa o mayor (ypT0-1) despu&#xe9;s del tratamiento neoadyuvante.</AbstractText><AbstractText Label="DISEO">Este fue un estudio retrospectivo.</AbstractText><AbstractText Label="AJUSTE">El estudio se realiz&#xf3; en un solo centro.</AbstractText><AbstractText Label="ESCENARIO">El estudio se realiz&#xf3; en un solo centro.</AbstractText><AbstractText Label="PACIENTES">Se compar&#xf3; a los pacientes tratados, tras tratamiento neoadyuvante (1996-2016), mediante escisi&#xf3;n local con respuesta patol&#xf3;gica mayor o completa al examen histol&#xf3;gico (grupo de microcirug&#xed;a endosc&#xf3;pica transanal), con los pacientes tratados mediante cirug&#xed;a radical con la misma respuesta patol&#xf3;gica (grupo de escisi&#xf3;n mesorrectal total).</AbstractText><AbstractText Label="INTERVENCIONES">Extirpaci&#xf3;n local mediante microcirug&#xed;a endosc&#xf3;pica transanal y cirug&#xed;a radical con escisi&#xf3;n mesorrectal total.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO">Morbilidad posoperatoria a corto plazo, resultado funcional a un a&#xf1;o despu&#xe9;s de la cirug&#xed;a (evaluado con una puntuaci&#xf3;n de evacuaci&#xf3;n y continencia) y resultado oncol&#xf3;gico a largo plazo.</AbstractText><AbstractText Label="LIMITACIONES">Las limitaciones de este estudio incluyen su dise&#xf1;o retrospectivo.</AbstractText><AbstractText Label="CONCLUSIN">Si se produce una respuesta patol&#xf3;gica mayor o completa despu&#xe9;s del tratamiento neoadyuvante, un abordaje con preservaci&#xf3;n de &#xf3;rganos mediante escisi&#xf3;n local parece ofrecer los mismos resultados oncol&#xf3;gicos que la cirug&#xed;a radical, pero tiene una menor tasa de morbilidad postoperatoria y mejores resultados funcionales un a&#xf1;o despu&#xe9;s de la cirug&#xed;a. Consulte Video Resumen en http://links.lww.com/DCR/B901 . (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pafundi</LastName><ForeName>Donato P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sionne</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietricola</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambacorta</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>U.O.C. Radioterapia Oncologica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentini</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>U.O.C. Radioterapia Oncologica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coco</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>U.O.C. Chirurgia Generale 2, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067369" MajorTopicYN="Y">Transanal Endoscopic Microsurgery</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35067503</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002255</ArticleId><ArticleId IdType="pii">00003453-202211000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7&#x2013;30.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638&#x2013;646.</Citation></Reference><Reference><Citation>Coco C, Rizzo G. Can standard surgical procedure reliably be avoided in major responders after radio(chemo)therapy? In: Valentini, V, Schmoll, H-J, van de Velde, CJH, eds. Multidisciplinary Management of Rectal Cancer. Berlin: Springer-Verlag. 2012:291&#x2013;304.</Citation></Reference><Reference><Citation>Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918&#x2013;928.</Citation></Reference><Reference><Citation>Coco C, Valentini V, Manno A, et al. Functional results after radiochemotherapy and total mesorectal excision for rectal cancer. Int J Colorectal Dis. 2007;22:903&#x2013;910.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711&#x2013;717.</Citation></Reference><Reference><Citation>Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8(suppl 3):21&#x2013;24.</Citation></Reference><Reference><Citation>Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001;8:801&#x2013;806.</Citation></Reference><Reference><Citation>Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131&#x2013;135.</Citation></Reference><Reference><Citation>Zmora O, Dasilva GM, Gurland B, et al. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum. 2004;47:1607&#x2013;1612.</Citation></Reference><Reference><Citation>Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56:1349&#x2013;1356.</Citation></Reference><Reference><Citation>Verseveld M, de Graaf EJ, Verhoef C, et al.; CARTS Study Group. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg. 2015;102:853&#x2013;860.</Citation></Reference><Reference><Citation>Rizzo G, Zaccone G, Magnocavallo M, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer. Eur J Surg Oncol. 2017;43:1488&#x2013;1493.</Citation></Reference><Reference><Citation>Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc. 2013;27:2860&#x2013;2867.</Citation></Reference><Reference><Citation>Doornebosch PG, Tollenaar RA, Gosselink MP, et al. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer. Colorectal Dis. 2007;9:553&#x2013;558.</Citation></Reference><Reference><Citation>De Graaf EJ, Doornebosch PG, Tollenaar RA, et al. Transanal endoscopic microsurgery versus total mesorectal excision of T1 rectal adenocarcinomas with curative intention. Eur J Surg Oncol. 2009;35:1280&#x2013;1285.</Citation></Reference><Reference><Citation>Coco C, Valentini V, Manno A, et al. Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer. Dis Colon Rectum. 2006;49:311&#x2013;318.</Citation></Reference><Reference><Citation>Gambacorta MA, Valentini V, Coco C, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies. Int J Radiat Oncol Biol Phys. 2004;60:139&#x2013;148.</Citation></Reference><Reference><Citation>Hospers GA, Punt CJ, Tesselaar ME, et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol. 2007;14:2773&#x2013;2779.</Citation></Reference><Reference><Citation>Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol. 2006;17:50&#x2013;56.</Citation></Reference><Reference><Citation>Valentini V, Coco C, Cellini N, et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys. 2001;51:371&#x2013;383.</Citation></Reference><Reference><Citation>Buess G, Hutterer F, Theiss J, B&#xf6;bel M, Isselhard W, Pichlmaier H. A system for a transanal endoscopic rectum operation. Chirurg. 1984;55:677&#x2013;680.</Citation></Reference><Reference><Citation>Sobin LH. TNM Classification of Malignant Tumors. 6th ed. Wiley-Liss Publication; 2001.</Citation></Reference><Reference><Citation>Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680&#x2013;2686.</Citation></Reference><Reference><Citation>Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery&#x2013;the clue to pelvic recurrence? Br J Surg. 1982;69:613&#x2013;616.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation></Reference><Reference><Citation>Gervaz P, Rotholtz N, Wexner SD, et al. Colonic J-pouch function in rectal cancer patients: impact of adjuvant chemoradiotherapy. Dis Colon Rectum. 2001;44:1667&#x2013;1675.</Citation></Reference><Reference><Citation>Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77&#x2013;97.</Citation></Reference><Reference><Citation>Marijnen CA, Kapiteijn E, van de Velde CJ, et al.; Cooperative Investigators of the Dutch Colorectal Cancer Group. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2002;20:817&#x2013;825.</Citation></Reference><Reference><Citation>Rahbari NN, Elbers H, Askoxylakis V, et al. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol. 2013;20:4169&#x2013;4182.</Citation></Reference><Reference><Citation>Horisberger K, Hofheinz RD, Palma P, et al. Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity? Int J Colorectal Dis. 2008;23:257&#x2013;264.</Citation></Reference><Reference><Citation>Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199&#x2013;6206.</Citation></Reference><Reference><Citation>Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29&#x2013;42.</Citation></Reference><Reference><Citation>Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965&#x2013;972.</Citation></Reference><Reference><Citation>Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:311&#x2013;315.</Citation></Reference><Reference><Citation>Myint AS, Thamphya B, Gerard JP. Does non-TME surgery of rectal cancer compromise the chance of cure? Preliminary surgical salvage data from OPERA phase III randomized trial. J Clin Oncol. 2021;39:12.</Citation></Reference><Reference><Citation>Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469&#x2013;479.</Citation></Reference><Reference><Citation>Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum. 2015;58:122&#x2013;140.</Citation></Reference><Reference><Citation>Rizzo G, Pafundi DP, Sionne F, et al. Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms. Tech Coloproctol. 2021;25:319&#x2013;331.</Citation></Reference><Reference><Citation>Stijns RCH, de Graaf EJR, Punt CJA, et al.; CARTS Study Group. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg. 2019;154:47&#x2013;54.</Citation></Reference><Reference><Citation>Serra-Aracil X, Pericay C, Golda T, et al.; TAU-TEM study group. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). Int J Colorectal Dis. 2018;33:241&#x2013;249.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>